Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer
Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer作者机构:Department of Surgery Sakai Municipal Hospital Osaka Japan Department of Surgery Osaka National Hospital Osaka Japan Department of Surgery Kinki Central Hospital Hyogo Japan Department of Internal Medicine Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan Department of Surgery Kinki University School of Medicine Osaka Japan Department of Surgery Kansai Rosai Hospital Hyogo Japan Department of Surgery Kitano Hospital & Research Institute Osaka Japan
出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))
年 卷 期:2006年第12卷第40期
页 面:6522-6526页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Gastric cancer CPT-11 CDDP Protracted Irinotecan Chemotherapy
摘 要:AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were: (1) histologi-cally proven measurable gastric cancer; (2) performance status of 0 or 1; (3) no prior chemotherapy or comple-tion of prior therapy at least 4 wk before enrollment; (4) adequate function of major organs; (5) no other active malignancy; and (6) written informed consent. The regi-men consisted of irinotecan (60 mg/m2) on d 1 and 15 by 24-h infusion and cisplatin (10 mg/m2) on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS: Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% (16/31), 60% (12/20), and 36% (4/11), respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia oc-curred in 11 (35%) patients, while grade 3 to 4 diarrhea or nausea occurred in 1 (3%) and 3 (10%) patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 (10%) patients. Other adverse events were mild and no treatment-related deaths ***: This regimen showed a high level of ac-tivity and acceptable toxicity in patients with metastatic gastric cancer.